Objectives Heat-shock protein-90 (HSP90) chaperone machinery is critical to the folding, stability and activity of several client proteins including many responsible for tumour initiation, progression and metastasis. Overexpression of HSP90 is correlated with poor prognosis of GI cancer. Key findings Pharmacological inhibitors of HSP90 suppress tumorigenic effects of HSP90 by suppressing angiogenesis, survival, metastasis and drug resistance in GI cancer. This review summarizes the role of HSP90 inhibitors in the treatment of GI cancer. Summary We have presented different antitumour mechanisms of HSP90 inhibitors in cancer treatment. Suppression of HSP90 signalling via specific and novel pharmacological inhibitors is a potentially novel therapeutic approach for patients with GI cancer for a better understanding and hence a better management of this disease.
Introduction
Gastrointestinal (GI) cancer is one of the most common types of cancer and one of the leading causes of death worldwide. Multidrug resistance, induction of metastasis and angiogenesis are involved in the pathogenesis of the disease. [1] Understanding the underlying mechanisms contributing to survival and progression of GI cancer could be essential for controlling the disease progression as well as improving current diagnostic and therapeutic strategies.
Heat-shock proteins (HSPs) are overexpressed under stress conditions divided into heavy and small molecular weight HSPs. Multiple biological functions have been reported for HSPs, including molecular chaperones, antioxidant and membrane transporter activities. [2] Moreover, it has been shown that HSPs are commonly expressed at high levels in cancers. [2] Accordingly, increasing evidence suggests that HSP90 plays a fundamental role in cancer progression by making a chaperone complex that folds, stabilizes and regulates oncogenic signal transduction molecules in cancer cells. [3, 4] HSP90 also binds to telomerase and prevents cells from senescence and erosion. [5] Further studies showed that HSP90-client proteins play pivotal roles in establishing cancer cell hallmarks such as insensitivity to growth inhibition signalling, self-sufficiency for growth signals, unlimited replicative potential, sustained angiogenesis and metastasis. [4] Suppression of HSP90 signalling via novel pharmacological inhibitors is a potentially novel therapeutic approach for patients with GI cancer. Understanding the molecular mechanisms that underlie the pathogenic signalling functions of HSP90 will be crucial for the successful development of novel drugs for a better management of GI track cancer. Hence, in this review, we provide an updated, comprehensive review of preclinical and clinical studies focusing on the role of HSP90 in GI cancer pathology including angiogenesis, apoptosis, metastasis and drug resistance ( Figure 1 ).
Angiogenesis
Angiogenesis is essential for unrestricted growth and dissemination of solid tumours. [6] Recently, several studies have been published about the involvement of HSP90 in tumour neovascularization in different cancers, specifically GI malignancies. [6, 7] For instance, Wang et al. showed a positive correlation between the expression of CD24 and HSP90 in colorectal cancer. Overexpression of CD24 is associated with microvessel density in colorectal cancer. Moreover, downregulation of CD24 decreases expression of vascular endothelial growth factor, a well-known angiogenic factor in cells. They showed that HSP90 regulates angiogenesis at least partially by modulating stability of CD24 in colorectal cancer cells. [8, 9] Consistently, it has been shown that HSP90 inhibitors elicit anti-angiogenic properties in tumour cells. [10] In line with this, Lang et al. showed that inhibition of HSP90 by 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) exerts anti-angiogenic effect by inhibiting the growth and vascularization of gastric tumours in tumour models. Consistently, inhibition of HSP90 suppresses multiple angiogenic pathways including epidermal growth factor receptor (EGFR) and human epidermal growth receptor-2 (Her-2) in gastric carcinoma cell line, TMK-1. [6] Moreover, administration of NVP-AUY922, a HSP90 inhibitor, decreases the phosphorylation and activation of several pro-angiogenic signalling pathways including protein kinase B (PKB), signal transducer and activator of transcription 3 (STAT3) and mitogen-activated protein kinase (MAPK) in human cholangiocarcinoma cells. [11] It has been shown that inhibition of HSP90 by ganetespib, an HSP90 inhibitor, inhibits hypoxia-inducible factor 1 alpha as well as STAT3, two potent regulators of angiogenesis in cellular, animal and clinical studies [12] (Table 1) . To further support the pro-angiogenic functions of HSP90 in gastrointestinal tumours, Moser et al. evaluated the effect of HSP90 inhibitor, NVP-AUY922, on pancreatic tumour growth and angiogenesis. They found that suppression of HSP90 decreases tumour growth as well as vascularization in pancreatic tumour models. [7] These results are consistent with the data reported by Ganji et al. [13] showing that inhibition of HSP90 with ganetespib, a HSP90 inhibitor, potently suppresses angiogenesis and tumour growth in xenografts of human pancreatic cancer.
These studies clearly support the hypothesis that HSP90-targeted therapy could be a novel approach in therapeutic strategies in a number of gastrointestinal cancers. [7] Ganji et al.
Pancreatic
Inhibition of HSP90 by Ganetespib suppresses angiogenesis and tumour growth in xenografts of human pancreatic cancer. [13] Nagaraju et al.
Colorectal
Inhibition of HSP90 by Ganetespib inhibits angiogenesis in cellular, animal and clinical studies. [12] Wang et al.
2016 Colorectal HSP90 regulates angiogenesis in colorectal cancer cells. [8] Shirota et al.
Cholangio
Inhibition of HSP90 by NVP-AUY922 suppresses several pro-angiogenic signalling pathways in human cholangiocarcinoma cells. [11] Lang et al.
Gastric
Inhibition of HSP90 by 17-DMAG elicits anti-angiogenic effect in gastric carcinoma cell line and tumour model. [6] Apoptosis Chen et al.
Cholangio
Co-administration of NVP-AUY922 (HSP90 inhibitor) and a PI3K/mTOR dual inhibitor increases apoptosis in cholangiocarcinoma cells and animal model. [23] Chen et al.
Inhibition of HSP90 by 17AAG and NVP-AUY922 exhibits pro-apoptotic functions in cholangiocarcinoma cells. [22] Lu et al.
Gastric
Inhibition of HSP90 by LD053 Inhibits gastric tumour growth in gastric cancer cells and xenografts in nude mice. [26] Chen et al.
Geldanamycin, an HSP90 inhibitor, induces apoptosis in gastric cancer adenoma cells. [21] Wang et al.
High expression of HSP90 is correlated with tumour aggressiveness and poor prognosis in patients with advanced gastric cancer. [15] Wang et al.
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Colon NVP-AUY922, a HSP90 inhibitor, induces apoptosis in colon cancer cells. [25] Saturno et al.
Colorectal
Co-treatment of TRAIL with HSP90 inhibitor, 17-AAG, enhances apoptosis in TRAIL-resistant xenograft models of human colorectal cancer. [24] Zhang et al.
Pancreatic
Celastrol increases cell apoptosis by blocking the Cdc37 and HSP90 interaction in pancreatic cancer cells and xenograft models. [17] Drug resistance Zhou et al.
Colorectal
Inhibition of HSP90 with 17-DMAG amplifies inhibitory effects of oxaliplatin on proliferation and invasion of colorectal cancer cells. [36] Fedier et al.
Colon
Radicicol, a novel HSP90 inhibitor, sensitizes colon cancer cells to cisplatin. [38] Mohammadi et al. 2016 Colorectal 17-AAG, an HSP90 inhibitor, synergistically potentiates the inhibitory effect of low concentrations of celecoxib in colorectal cancer cells. [35] Nagaraju et al.
Colorectal
Ganetespib, an HSP90 inhibitor, inhibits survival and proliferation in colorectal cancer cells and animal models and sensitizes cancer cells to 5-FU treatment. [37] Wainberg et al.
Gastric
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant gastric cancer. [42] Sarkar et al.
Pancreatic
Oxidative inhibition of HSP90 attenuates pancreatic adenocarcinoma in vitro and in vivo. [16] Metastasis Moser et al.
Administration of NVP-AUY922, an HSP90 inhibitor, downregulates expression of FAK in pancreatic cancer cells. [7] Zhang et al.
Metastasis of pancreatic islet tumours is suppressed more than 80% by administering celastrol, an HSP90 inhibitor, in mice. [17] Wang et al.
2013 Gastric HSP90 expression is correlated with tumour depth invasion and lymph node metastasis in gastric cancer. [15] Zuo et al.
Gastric
A positive correlation between HSP90a expression and lymph node gastric cancer metastasis. [45] Moser et al.
2007 Colorectal 17-DMAG, an HSP90 inhibitor, decreases cell metastasis and invasiveness in human colorectal cancer cells. [52] Apoptosis Apoptosis is a tightly regulated physiological process of programmed cell death which protects the genomic integrity and maintains homoeostasis and cellular balance in normal tissues. Defective apoptosis contributes to carcinogenesis and tumour development. [14] There are studies supporting a correlation between overexpression of HSP90 with increased survival of different cancer cells. [15, 16] Consistently, Sarkar et al. [16] showed that mahanine, an apoptosis inducer, elicits pro-apoptotic functions by enhancing disruption of the HSP90-Cdc37 complex, leading to accumulation of reactive oxygen species in pancreatic ductal adenocarcinoma cells, Panc-1. This is consistent with the results of another study conducted by Zhang et al. showing that celastrol, a quinone methide triterpene derived from the medicinal plant Tripterygium wilfordii, increases cell apoptosis by blocking the Cdc37 and HSP90 interaction in pancreatic cancer cells. This disruption induces degradation of HSP90-client proteins, resulting in apoptosis in Panc-1 cell line and Panc-1 xenograft model as well. [17] Regulation of tumour necrosis factor receptor (TNFR-1) signalling is another suggested mechanism involved in HSP90-induced cell survival in cancer cells. [18] TNF via binding to TNFR induces apoptosis in stimulated cells. [19] However, binding of receptor interacting protein (RIP) to TNFR-1 activates anti-apoptotic signalling including NFkB pathway, thereby protecting cells towards the TNFinduced apoptosis. HSP90 contributes to the stabilization of RIP. [18] Moreover, HSP90 could also affect TNFmediated NF-kB activity through the IKK complex in which Cdc37 and HSP90 are found to be two members of its components. [20] To further support the regulatory role of HSP90 in cancer cell apoptosis, Chen et al. [21] showed that geldanamycin, an HSP90 inhibitor, induces apoptosis in gastric cancer SGC-7901 adenoma cells. Similarly, administration of HSP90 inhibitors, 17AAG and NVP-AUY922, exhibits potent pro-apoptotic functions in cholangiocarcinoma cells. [22] In line with this, co-administration of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor, NVP-BEZ235, with HSP90 inhibitor, NVP-AUY922, synergistically increases apoptosis in both cholangiocarcinoma cells and thioacetamide-induced cholangiocarcinoma animal model. [23] Consistently, Saturno et al. investigated the effect of HSP90 inhibitor on TNF-related apoptosis-inducing ligand (TRAIL) resistance in colorectal cancer. They showed that co-treatment of TRAIL with HSP90 inhibitor, 17-AAG, considerably increases apoptosis as compared with a single treatment group in TRAIL-resistant xenograft models of human colorectal cancer. [24] Consistently, Wang et al. showed that NVP-AUY922, a HSP90 inhibitor, induces apoptosis in colon cancer cells. Further studies showed that KRAS mutant colon cancer cells are more susceptible to apoptosis induced by AUY922 compared with wild-type, supporting the role of KRAS signalling in pro-apoptotic signalling functions of the HSP90 inhibitor in colon cancer cells. [25] Consistent with the pro-apoptotic effect of HSP-90 pharmacological inhibitors on colorectal cancer, Lu et al. showed that LD053, an HSP90 inhibitor, upon binding to the N-terminus of HSP90, enhances dissociation of cdc37 from HSP90, leading to inhibition of pro-survival signalling pathways including c-Raf/Mek/Erk as well as PI3K/Akt in gastric cancer cells. Consistent with cellular studies, administration of LD053 inhibits growth of gastric cancer cell xenografts in nude mice. [26] Further studies suggested that inhibition of HSP90 could block growth factor-induced Akt activation in stimulated cells. [27] Consistently, it has been demonstrated that inhibition of Akt-HSP90 interaction results in dephosphorylation and inactivation of the Akt signalling pathway, leading to enhanced cell sensitivity to apoptotic stimuli. [28] These results clearly support the role of HSP90 in survival of GI cancer cells and provide further evidence for the therapeutic potency of targeting HSP90 by specific pharmacological inhibitors as a novel strategy for cancer therapy.
Drug resistance
According to the diverse nature and complexity of genetic and epigenetic variations in tumour cells, the emergence of drug resistance in cancer therapy is still unavoidable. Studies have suggested that identification of potent molecular targets involved in several signalling pathways would be one of the possible strategies in overcoming resistance and producing desirable outcomes. [29, 30] HSP90 is involved in modulating various oncogenic client proteins implicated in crucial pathways associated with a malignant phenotype. [3, 31] Studies have shown that inhibition of HSP90 results in significant anticancer effects as well as promoting the efficacy of anticancer drugs, thereby allowing administration of anticancer agents at lower concentration than normal, all of which prevents drug resistance. [32] [33] [34] Accordingly, Mohammadi et al. investigated the effect of combination therapy of celecoxib, a COX-2 inhibitor, and 17-AAG, an HSP90 inhibitor, on a colorectal cancer cell line, HT-29. They showed that 17-AAG synergistically potentiates the inhibitory effect of low concentrations of celecoxib in a combined treatment group. [35] Consistently, administration of HSP90 inhibitor, 17-DMAG, amplifies inhibitory effects of oxaliplatin on both proliferation and invasion of two colorectal cancer cell lines, SW480 and HCT116. [36] Similarly, Nagaraju et al. [37] showed that ganetespib, an HSP90 inhibitor, inhibits survival and proliferation of colorectal cancer cells in cellular and animal models. More importantly, they observed that ganetespib sensitizes cancer cell lines to 5-fluorouracil (5-FU) treatment. Consistent with these findings, it has been shown that Radicicol, a novel HSP90 inhibitor, sensitizes colon cancer cells to cisplatin. [38] Further studies suggested that HSP90 inhibitors decrease the intrinsic evolvability of tumour cells. [39] Moreover, studies have suggested that HSP90 could also be involved in resistance to growth factor receptor Her2-targeted drugs by stabilizing the oncogenic Her2 protein in cancer cells. [6, 40, 41] In this view, Wainberg et al. evaluated the clinical potency of NVP-AUY922, an HSP90 inhibitor, in Her-2 overexpressed gastric cancer cell lines as well as xenograft models. Results showed that co-administration of AUY922 and trastuzumab suppresses Her-2 expression and induces apoptosis by arresting cells at G2 cell cycle phase. Further studies showed that HSP90 inhibitor dramatically increases antitumour effects of trastuzumab in a trastuzumab-resistant gastric cancer xenograft model as well. [42] 
Metastasis
Cancer metastasis briefly includes alteration in cell motility, changes in cell adhesion properties, homing in distant tissues far away from their primary source, and, thus neoangiogenesis to survive. A number of complex processes are needed to assist in tumour cell growth and metabolism in the distant organs. [43] HSP90 is one of the factors involved in these processes acting through maintaining the stability of a wide range of signalling molecules implicated in metastatic pathways. [44] In line with this, Zuo et al. [45] showed that there is a positive correlation between HSP90a expression and lymph [15] reported that HSP90 expression is correlated with tumour depth invasion (P < 0.001) and lymph node metastasis (P < 0.001). Consistently, HSP90 inhibitors could be potent agents to suppress HSP-90-induced invasion and metastasis in tumour cells. In line with this, Zhang et al. [17] showed that metastasis of pancreatic islet tumours is suppressed more than 80% by administering celastrol, a potent HSP90 inhibitor, in mice. Similarly, it has been reported that administration of NVP-AUY922, an HSP90 inhibitor, downregulates expression of focal adhesion kinase (FAK), an essential factor in tumour cell invasion, in pancreatic cancer cells. [7] FAK upon interaction with integrin forms a complex which acts as a scaffold for signalling molecules implicated in cell adhesion process. [46] Consistently, using another HSP90 inhibitor, geldanamycin, enhances FAK degradation and markedly reduces the half-life of newly synthesized FAK protein in several cancer cell types including breast, prostate and Ewing's sarcoma. [47] Moreover, geldanamycin, a HSP90 inhibitor, impairs formation of focal adhesions and inhibits tyrosine phosphorylation of FAK and prevents FAK-mediated cell migration and metastasis in stimulated cells. [48] [49] [50] Furthermore, treating cells with NVP-AUY922, an HSP90 inhibitor, downregulates the expression of c-Met, a critical factor in metastatic progression of tumour cells [51] in pancreatic cancer cells. [7] Similarly, Moser et al. [52] showed that 17-DMAG, an HSP90 inhibitor, significantly decreases cell metastasis and invasiveness by inhibiting phosphorylation of FAK, c-Met and epidermal growth factor receptor (EGFR) in human colorectal cancer cells. These results are in line with the study in which c-Met and EGFR have been reported to have a crucial role in colorectal cancer metastasis. [53, 54] These results support the role of HSP90 inhibitors in impairing invasive activity of cancer cells by modulating different pathways and proteins function, including c-Met, EGFR and also FAK, which could be considered as potent targets in cancer therapy regimens.
Clinical studies
Several published clinical trials have been developed to assess the efficacy of HSP90 inhibitors on cancer therapy. For instance, Phase I study of BIIB021, a synthetic HSP90 inhibitor, showed the well tolerability of the drug and broad application against tumours with acquired multidrug resistance. [55, 56] A phase II clinical trial of BIIB021 has been also undertaken in subjects with gastrointestinal stromal tumour (GIST) refractory to imatinib and sunitinib. Results demonstrated that inhibition of HSP90 by BIIB021 enhances metabolic responses in >20% of patients. [57] In another phase 1 study, Wagner et al. [58] showed that IPI-504, an HSP90 inhibitor, is well tolerated and elicits some antitumour activities in patients with GISTs. Similarly, a phase I dose escalation study of AUY922, an HSP90 inhibitor, showed that up to 70 mg/m 2 concentration of the inhibitor is well tolerated with acceptable toxicity in subjects with advanced solid tumours. Moreover, a phase II single-agent and combination therapy have been initiated for this inhibitor in patients with gastric cancer. [59] Furthermore, there are several unpublished clinical trials underway investigating the potential therapeutic efficacy of HSP90 inhibitors in the treatment of GI cancers. Table 2 summarizes clinical trials on HSP90 inhibitors for GI tract cancers. Further updated information can also be found on the www.clinicaltrials.gov website.
Conclusion
In this review, we summarized regulatory signalling functions of HSP90 in GI cancer pathology. HSP90 regulates angiogenesis, apoptosis, metastasis and drug resistance in gastrointestinal (GI) cancer cells. Elevated levels of HSP90 are correlated with pro-angiogenic, pro-survival, increased metastasis potential, increased drug resistance and poor prognosis of GI cancer. These studies clearly support the role of HSP90 inhibitors as novel therapeutic approach in cancer therapy.
Although the tumorigenic function of HSP90 has been intensively investigated, the molecular mechanisms of these responses are poorly understood. Further studies are required to determine the exact mechanism of HSP90 functions on patients with GI cancer. Unravelling underlying mechanisms of these effects could assist in understanding the involved factors and pathways and could therefore help to design novel agents to regulate the pathological responses in the tumour micro-environment and have a greater clinical significance in terms of the treatment of GI cancer-associated complications.
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